Comparing the Risks and Benefits of Adjunctive Medications for PTSD Presenter Name Beth Cohen, MD MAS San Francisco VA Health Care System & University of California, San Francisco September 19, 2019
Beth Cohen • Has nothing to disclose. 2
Challenges in Pharmacologic Treatment of PTSD • In RCTs of first-line serotonin reuptake inhibitor (SRI) therapy: - 40% of patients do not have clinically significant improvements in PTSD symptoms - 70% do not achieve remission • Little evidence on what to do next 3
Our Initial Research Goal • Many patients are prescribed antipsychotic medications - mixed evidence in trials - only 1 trial specifically in patients already on SRIs - many concerning metabolic side effects To determine the risks and benefits of adding antipsychotics to an SRI in patients with PTSD? 4
Feedback from Partners • Patient partners: - many different types of medications used - “you feel like a guinea pig” - wanted information to participate in shared decision making • Stakeholder partners: - providers want to “do something” - no studies compare strategies, so there is no guidance 5
Our Updated Research Goal • To compare the risks and benefits of several medications that are commonly added to SRIs: - antipsychotics - mirtazapine - tricyclic antidepressants - prazosin 6
Methods • National VA electronic records 2007-2015 • PTSD but no bipolar/psychotic disorder • SRI ≥ 30 days • Augmenting medication added for ≥60 days: - Antipsychotics (N=70,900) - Mirtazapine (N=54,672) - Tricyclics (N=21,984) - Prazosin (N=100,269) • Compare outcomes in 1 year before vs. after addition of augmenting medication 7
Methods: Outcomes • Benefits: - PTSD symptoms (PTSD Checklist) - Mental health ER visits and hospitalizations - Suicidality 8
Methods: Outcomes • Risks: - Weight - Blood pressure - Labs: cholesterol, glucose, hemoglobin A1c - Cardiovascular disease events 9
Results: PTSD Symptoms - On average, each group had very small improvements after addition of augmenting med - Similar by medication class 10
Results: PTSD Symptoms - PTSD symptoms gradually increase and peak around time Rx is added - In 3-4 months, symptoms return to baseline levels 11
Mental Health Emergency Room Visits - Augmenting med groups have different baseline mental health ER visit rates but % improvement is similar - In contrast to PTSD symptoms, there were more substantial average reductions ER visits 12
Suicidal Thoughts - Small but clinically meaningful reductions in suicidal thoughts - Biggest improvements with prazosin and antipsychotics 13
Weight - Most weight gain with antipsychotics/mirtazapine and no return to baseline 14
Hemoglobin A1c - Greatest increase with mirtazapine and tricyclics 15
Other Metabolic Outcomes • Triglycerides: increased 3-8% except for prazosin • No significant increases in blood pressure or cholesterol, but: - 20-30% increased/started medications to treat • Increase in diagnoses of cardiovascular disease events 16
Summary • 2 nd line medications may be useful when PTSD symptoms worsen • Benefits similar across classes • Use associated with weight gain and other metabolic risks: mirtazapine>antipsychotics>tricyclics>prazosin 17
Next Steps • Presenting locally and nationally • Working with stakeholder partners- NCPTSD, VA Office of Mental Health Operations • Compare to a “control” group with inadequate SRI response • Identify which patients are most likely to benefit 18
Thank You • Project Team: Nancy Bernardy, Shira Maguen, Thomas Neylan, Annie Ryder, Karen Seal, Janet Tang, Ana-Marie Urbieta, Ilse Weichers, Anne Woods, Dmitri Young • VA Measurement Science QUERI: Mary Whooley, Craig Meyer, Niru Krishnamurthi, David Schopfer, Hui Shen, Katherine Williams, Ning Zhang • Funding: PCORI 19
Learn More • www.pcori.org • info@pcori.org • #PCORI2019 20
Questions? 21
Thank You! Beth Cohen Comparing the Risks and Benefits of Adjunctive Medications for PTSD September 19, 2019 22
Adjunctive Therapies to Neonatal Ventilation Sunil Sinha Professor of
Immunotherapy Case Studies Weighing risks and benefits when risks are
www.nina.no Cooperation and expertise for a sustainable future Benefits of
GLOBAL RISKS GLOBAL RISKS GLOBAL RISKS - GLOBAL RISKS - - - GLOBAL RISKS
Wireless Network Security Vedavyas Duggirala CS 6204, Spring 2005 1
Arbeitnehmerschutz und Gesundheit am Bau in der BRD ( Germany - Analyzing and
Children on Social Media: Risks, Benefits and Filters Beatrice Hayes Dr Dawn
Presentation to the Select Committee on the Risks and Benefits of Hydraulic
Lecture 1/Chapter 1 Benefits & Risks of Statistics Organization of
How to find, filter, and format Evidence-based Information on the Benefits
6/13/2018 Disclosures Current clinical trial funded by Auspex/Teva Past
LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki
Sa fe ly Re duc ing the Use o f Antipsyc ho tic Me dic a tio ns An Ove
QUESTIONS Is carotid artery stenting (CAS) FEASABLE ? Carotid Endarterectomy
Anticoagulatie en de oudere patint: Terughoudenheid gerechtvaardigd of niet?
What Goes Together: Peanut Butter & Jam, Cookies & Milk Antiplatelets
RI Antipsychotic Med Reduction Challenges to the QIN-QIO 11 th Statement of
Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love,
CARE TALKS Sustaining Practice Now That The Project Is Officially Over More
Working to Eliminate Inappropriate Antipsychotic Medication Use
20112015 Psychosis: an illness of young Improving conditions for recovery:
Quality of Care in Medi-Cal: Understanding HEDIS for Children in Foster Care